Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07546214 · ClinicalTrials.gov registry record · Phase 1
A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.
A Phase 1 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 575
- Enrollment target
NCT07546214 is a Phase 1 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 575 participants.
The verdict
NCT07546214, a Phase 1 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 575 participants
- Enrollment target
Study Summary
To demonstrate therapeutic equivalence and safety of Tapinarof Cream, 1% (Sun pharma Canada, Inc.) and Vtama® (Tapinarof) Cream, 1% in the treatment of plaque psoriasis.
Interventions
- DRUG Placebo Control
- DRUG Tapinarof Cream, 1%
- DRUG Vtama® (Tapinarof) Cream, 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 575 participants |
| Start Date | 2025-10-13 |
| Est. Completion | 2026-03-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07546214
The ClinicalTrials.gov registry entry for NCT07546214 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 575 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Control is the first listed.
NCT07546214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07546214 about?
NCT07546214 is a clinical study titled "A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.". To demonstrate therapeutic equivalence and safety of Tapinarof Cream, 1% (Sun pharma Canada, Inc.) and Vtama® (Tapinarof) Cream, 1% in the treatment of plaque psoriasis.
What is the current status of trial NCT07546214?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 575 participants. The study started on 2025-10-13. Estimated completion is 2026-03-18.
What interventions are being tested in trial NCT07546214?
The interventions under investigation include: Placebo Control (DRUG), Tapinarof Cream, 1% (DRUG), Vtama® (Tapinarof) Cream, 1% (DRUG).
Who is sponsoring clinical trial NCT07546214?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.